Evofem Biosciences to Present at H.C. Wainwright BioConnect Conference

Rhea-AI Summary

Evofem Biosciences (NASDAQ: EVFM) announced its participation in the H.C. Wainwright BioConnect Virtual Conference from January 10–13, 2022. CEO Saundra Pelletier will present updates on the company's hormone-free contraceptive Phexxi® and its pipeline, including an ongoing Phase 3 clinical trial for EVO100 targeting chlamydia and gonorrhea, as well as a new Multipurpose Prevention Technology candidate for HIV. The presentation will be available on-demand starting 7:00 AM ET on January 10.

SAN DIEGO, Jan. 4, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that the Company will present and host one-on-one meetings at the H.C. Wainwright BioConnect Virtual Conference being held from January 10 – 13, 2022.

Chief Executive Officer Saundra Pelletier will provide an update on the commercialization of Evofem's hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate) as well as the Company's pipeline, including the ongoing Phase 3 clinical trial evaluating EVO100 for the prevention of chlamydia and gonorrhea in women and the recently announced Multipurpose Prevention Technology (MPT) product candidate for indications including the prevention of HIV in women.

The Company's presentation will be available for on demand listening beginning at 7:00am ET on Monday, January 10, 2022 through the H.C. Wainwright BioConnect conference portal and via https://evofem.investorroom.com/HCWJan22 for 90 days.

To request a one-on-one meeting with Evofem during the conference, please contact your H.C. Wainwright representative or email ir@evofem.com.

About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (chlamydia, gonorrhea and HIV). The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com and evofem.com.

Phexxi^® is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-to-present-at-hc-wainwright-bioconnect-conference-301453189.html

SOURCE Evofem Biosciences, Inc.

FAQ

What is Evofem Biosciences presenting at the H.C. Wainwright BioConnect Conference?

Evofem Biosciences is presenting updates on its hormone-free contraceptive Phexxi® and its clinical pipeline, including EVO100 for chlamydia and gonorrhea.

When is the H.C. Wainwright BioConnect Conference?

The H.C. Wainwright BioConnect Conference will take place from January 10 to January 13, 2022.

Who is the CEO of Evofem Biosciences?

The CEO of Evofem Biosciences is Saundra Pelletier.

When will Evofem's presentation be available for on-demand listening?

Evofem's presentation will be available for on-demand listening starting at 7:00 AM ET on January 10, 2022.

How can I request a one-on-one meeting with Evofem during the conference?

To request a one-on-one meeting with Evofem during the conference, contact your H.C. Wainwright representative or email ir@evofem.com.

What is the focus of Evofem's Phase 3 clinical trial?

Evofem's Phase 3 clinical trial focuses on evaluating EVO100 for the prevention of chlamydia and gonorrhea in women.

What is Phexxi®?

Phexxi® is Evofem's hormone-free contraceptive vaginal gel, approved by the FDA for on-demand use.